Ethnicity's Impact on Myeloma Outcomes After Stem Cell Transplant | Frances Cervoni, MD | #ASH24

Ethnicity's Impact on Myeloma Outcomes After Stem Cell Transplant | Frances Cervoni, MD | #ASH24
Beating T-Cell Exhaustion: The Future of Myeloma Care | Marta Chesi , PhD & Erin Meermeier, PhD | #ASH24
New Myeloma Combinations Using CELMoD’s and Antibody Drug Conjugates | Paul Richardson, MD | #ASH24
Updates from ASH-a-Palooza and Mentoring in Hematology/Oncology | Tax Kourelis, MD | #ASH24
Teclistamab Step-Up Dosing to Prevent CRS in Relapse/Refractory MM | Jeffrey Matous, MD | #ASH24
Bone Marrow Spatial Signatures Predict Outcomes in R/R Myeloma Patients | Yoshinobu Konishi, MD, PhD | #ASH24
A Faster Tandem CAR T-Cell Product, Zamto-Cel Being Studied in DLBCL | Nirav Shah, MD, MSHP | #ASH24
Bispecific Antibody, AZD0486 Attacks a New Target in DLBCL | Sameh Gaballa, MD | #ASH24
Exploring Barriers to CAR T-Cell Therapy in Blood Cancer Patients | Yannis Valtis, MD | #ASH24
Glofitamab for Relapsed/Refractory Large B-cell Lymphomas | Joshua Brody, MD | #ASH24
Frailty’s Impact on Outcomes in Older MM Patients Treated with Bispecifics | Nadine Abdallah, MD| #ASH24
A Unique BTK Inhibitor, Pirtobrutinib for Patients with Pretreated CLL | Jeff Sharman, MD | #ASH24
Duvelisib + Venetoclax: A Time-Limited, All Oral Option for CLL | Jennifer Crombie, MD | #ASH24
Promising Results for Odronextamab in Post CAR T Patients with DLBCL | Jennifer Crombie, MD | #ASH24
Understanding the ASH Research Collaborative- COSMIC Study | Saad Usmani, MD | #ASH24
Belantamab + Standard of Care for Newly Diagnosed Myeloma (DreaMM-9) | Saad Usmani, MD | #ASH24
Social Determinants of Health Impact Myeloma FISH Testing | Amy Pierre, MSN, RN, ANP-BC | #ASH24
Dara-CyBorD vs CyBorD in Newly Diagnosed AL Amyloidosis| Hans Lee, MD | #ASH2024